BR0211561A - Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos - Google Patents

Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos

Info

Publication number
BR0211561A
BR0211561A BR0211561-1A BR0211561A BR0211561A BR 0211561 A BR0211561 A BR 0211561A BR 0211561 A BR0211561 A BR 0211561A BR 0211561 A BR0211561 A BR 0211561A
Authority
BR
Brazil
Prior art keywords
compounds
compositions
arylsulfonyl
receptor affinity
indole compounds
Prior art date
Application number
BR0211561-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Jian-Min Fu
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0211561A publication Critical patent/BR0211561A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0211561-1A 2001-08-03 2002-08-01 Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos BR0211561A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30983201P 2001-08-03 2001-08-03
US32688501P 2001-10-03 2001-10-03
PCT/US2002/024759 WO2003011284A1 (en) 2001-08-03 2002-08-01 5-arylsulfonyl indoles having 5-ht6 receptor affinity

Publications (1)

Publication Number Publication Date
BR0211561A true BR0211561A (pt) 2004-11-30

Family

ID=26977033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211561-1A BR0211561A (pt) 2001-08-03 2002-08-01 Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos

Country Status (7)

Country Link
US (1) US6565829B2 (enExample)
EP (1) EP1411925A1 (enExample)
JP (1) JP2005500345A (enExample)
BR (1) BR0211561A (enExample)
CA (1) CA2452743A1 (enExample)
MX (1) MXPA04001089A (enExample)
WO (1) WO2003011284A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
CA2521177C (en) * 2003-04-25 2012-12-04 Allergan, Inc. Use of a botulinum neurotoxin to alleviate various disorders
ES2313002T3 (es) * 2003-05-09 2009-03-01 Laboratorios Del Dr. Esteve, S.A. Uso de derivados de sulfonamida para la fabricacion de un medicamento para la profilaxis y/o tratamiento de la ingestion de alimentos.
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
DE102004048716A1 (de) * 2004-10-06 2006-04-20 Dr. Willmar Schwabe Gmbh & Co. Kg Verwendung von Lavendelöl zur Prophylaxe und Behandlung von Neurasthenie, Somatisierungsstörungen und von anderen stress-assoziierten Erkrankungen
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
ES2306275T3 (es) * 2004-12-21 2008-11-01 F. Hoffmann-La Roche Ag Derivados de cromano y sus usos como ligandos dde receptores 5-ht.
PT1831159E (pt) * 2004-12-21 2010-03-03 Hoffmann La Roche Derivados de tetralina e de indano e as suas utilizações
BRPI0515835A (pt) * 2004-12-21 2008-08-12 Hoffmann La Roche derivados de tetralina e de indano e seus usos
PT1919896E (pt) * 2005-08-12 2010-02-26 Suven Life Sciences Ltd Derivados de aminoaril sulfonamida como ligandos funcionais de 5-ht6
WO2007051735A1 (en) * 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
WO2007147763A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
WO2007147883A1 (en) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
PL343007A1 (en) 1998-02-25 2001-07-30 Genetics Inst Inhibitors of phospholipase enzymes
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
SI1859798T1 (sl) * 2001-03-29 2016-07-29 Eli Lilly And Company N-(2-ariletil) benzil amini kot antagonisti 5-ht6 receptorja

Also Published As

Publication number Publication date
US6565829B2 (en) 2003-05-20
EP1411925A1 (en) 2004-04-28
CA2452743A1 (en) 2003-02-13
WO2003011284A1 (en) 2003-02-13
JP2005500345A (ja) 2005-01-06
MXPA04001089A (es) 2004-05-20
US20030060498A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
MXPA04001089A (es) 5-arilsulfonil indoles que tienen afinidad por el receptor de 5-ht.
BRPI0414541A8 (pt) compostos heterocíclicos fundidos, seu uso, método de preparação de compostos intermediários e método para estudar distúrbios mediados por serotonina
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
PT751939E (pt) Naftilamidas como agentes para o sistema nervoso central
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
BRPI0412695A (pt) derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1
BR0012084A (pt) Compostos, composição farmacêutica e usos dos compostos
DK0411668T3 (da) Central-cholecystokinin-antagonister til behandling af psykiatriske forstyrrelser
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
ECSP034559A (es) Nuevos compuestos no-imidazol
ATE289593T1 (de) Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
BR0015962A (pt) Compostos tendo ligações multiplas que são agonistas de receptor adrenérgico (beta)2 úteis no tratamento e prevenção de doenças respiratórias
BR0315681A (pt) Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
GT200000011A (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales.
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
BRPI0110024B8 (pt) derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
HN1999000146A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.